Anti-influenza therapy: The emerging challenge of resistance

Therapy

Volumn 6, Issue 6, 2009, Pages 883-891

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adamantine; Amantadine; Influenza; M2 inhibitor; Neuraminidase inhibitor; Oseltamivir; Peramivir; Resistance; Rimantadine; Zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; M2 INHIBITOR; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INSOMNIA; MUTATION; NONHUMAN; REVIEW; SEIZURE;

EID: 70449669428     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.61     Document Type: Review

References (74)

1. Hayden FG, Palese P: Influenza Virus. In: Clinical Virology - 2nd edition. Richman DD, Whitley RJ, Hayden FG (Eds). ASM Press, Washington, DC, USA, 891-920 (2002).
2. Fiore AE, Shay DK, Broder K et al.: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep. 57(RR-7), 1-60 (2008).
3. Thompson WW, Shay DK, Weintraub E et al.: Influenza-associated hospitalizations in the United States. JAMA 292(11), 1333-1340 (2004). ■■ Provides data on the rates of hospitalization related to influenza in the USA.
4. Thompson WW, Shay DK, Weintraub E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003). (Pubitemid 36068705)
5. Nichol KL, Lind A, Margolis KL et al.: The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 333(14), 889-893 (1995).
6. Ison MG, Hayden FG: Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr. Opin. Infect. Dis. 15(4), 355-367 (2002).
7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
8. The Writing Committee of the World Health Organization: Consultation on avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353(13), 1374-1385 (2005). ■■ A key review of salient features related to H5N1 disease in humans, including epidemiology, risk factors, prevention and management.
9. Hayden FG, Aoki FY: Amantadine, rimantadine, and related agents. In: Antimicrobial Therapy and Vaccines. Yu VL, Merigan TCJ, Barriere SL (Eds). Williams & Wilkins, MD, USA, 1344-1365 (1999).
10. Moscona A: Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353(13), 1363-1373 (2005).
11. Dharan NJ, Gubareva LV, Meyer JJ et al.: Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301(10), 1034-1041 (2009). ■■ A detailed report of the emergence and spread of oseltamivir-resistant H1N1 viruses, with details about clinical course and how it relates to susceptible strains.
12. Lackenby A, Hungnes O, Dudman SG et al.: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13(5) (2008). ■■ An outline of the epidemiology and virology of the emergence of oseltamivir-resistant H1N1 in Europe.
13. Bright RA, Shay D, Bresee J et al.: High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-2006 influenza season. MMWR Morb. Mortal. Wkly Rep. 55(2), 44-46 (2006).
14. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI: Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295(8), 891-894 (2006). ■■ The hallmark paper that highlighted the spread of M2-resistant H3N2 viruses in the USA and its impact on clinical care of patients.
15. Nicholson KG, Wood JM, Zambon M: Influenza. Lancet 362(9397), 1733-1745 (2003).
16. Hayden FG, Minocha A, Spyker DA, Hoffman HE: Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. 28(2), 216-221 (1985). (Pubitemid 15019952)
17. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr: Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med. 160(10), 1485-1488 (2000). (Pubitemid 30327452)
18. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui KJ, Gohd R: Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch. Intern. Med. 146(9), 1751-1756 (1986).
19. Colman PM, Hoyne PA, Lawrence MC: Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67(6), 2972-2980 (1993).
20. Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M: Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322(7286), 577-579 (2001). (Pubitemid 32234531)
21. Beigel J, Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78(1), 91-102 (2008). ■ A detailed review of anti-influenza agents currently under study for the treatment of influenza of man.
22. Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1), S3-S13 (2009). ■ A review of anti-influenza agents currently under study for the treatment of influenza in man.
23. De Clercq E: Antiviral agents active against influenza A viruses. Nat. Rev. 5(12), 1015-1025 (2006).
24. Ong AK, Hayden FG: John F. Enders lecture 2006: antivirals for influenza. J. Infect. Dis. 196(2), 181-190 (2007).
25. Astrahan P, Kass I, Cooper MA, Arkin IT: A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins 55(2), 251-257 (2004). (Pubitemid 38437485)
26. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH: Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18(Suppl. B), 19-29 (1986).
27. Hurt AC, Ho HT, Barr I: Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev. Anti Infect. Ther. 4(5), 795-805 (2006).
28. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ: Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J. Infect. Dis. 164(5), 969-972 (1991). ■ An important study that defined that M2-resistant influenza appears to be equally virulent as the wild-type virus.
29. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG: Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193(6), 760-764 (2006).
30. Hall CB, Dolin R, Gala CL et al.: Children with influenza A infection: treatment with rimantadine. Pediatrics 80(2), 275-282 (1987). (Pubitemid 17126807)
31. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321(25), 1696-1702 (1989). ■■ A key early study that documented the emergence and transmission of M2 inhibitor resistance among family members exposed to individuals treated with M2 inhibtors.
32. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother. 35(9), 1741-1747 (1991).
33. Kiso M, Mitamura K, Sakai-Tagawa Y et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436), 759-765 (2004). (Pubitemid 39165094)
34. Englund JA, Champlin RE, Wyde PR et al.: Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26(6), 1418-1424 (1998).
35. Deyde VM, Xu X, Bright RA et al.: Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196(2), 249-257 (2007). (Pubitemid 47047464)
36. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S et al.: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009). ■■ Key review of the emergence of swine-origin influenza virus H1N1 in the USA and Mexico.
37. Cox NJ: FDA H5N1 Update: classification of H5N1 viruses and development of vaccine reference strains. US Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (2007).
38. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV: Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 193(6), 765-772 (2006).
39. Bright RA, Medina MJ, Xu X et al.: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005). (Pubitemid 41393595)
40. Gubareva LV: Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103(1-2), 199-203 (2004). ■ A detailed review of neuraminidase inhibitor (NAI) resistance mechanisms.
41. McKimm-Breschkin J, Trivedi T, Hampson A et al.: Neuraminidase sequence ana lysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47(7), 2264-2272 (2003). (Pubitemid 36753582)
42. Aoki FY, Boivin G, Roberts N: Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 12(4 Pt B), 603-616 (2007). ■■ A detailed review of NAI resistance mechanisms and testing strategies. (Pubitemid 47235503)
43. Lackenby A, Thompson CI, Democratis J: The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 21(6), 626-638 (2008).
44. Collins PJ, Haire LF, Lin YP et al.: Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453(7199), 1258-1261 (2008).
45. Roberts NA: Treatment of influenza with neuraminidase inhibitors: virological implications. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356(1416), 1895-1897 (2001).
46. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y: High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 188(1), 57-61 (2003). (Pubitemid 36829742)
47. Ward P, Small I, Smith J, Suter P, Dutkowski R: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1), I5-I21 (2005). (Pubitemid 40331165)
48. Whitley RJ, Monto AS: Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J. Infect. Dis. 194(Suppl. 2), S133-S138 (2006).
49. Stephenson I, Democratis J, Lackenby A et al.: Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 48(4), 389-396 (2009).
50. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM: Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 301(10), 1042-1046 (2009). ■■ A case series highlighting the importance of oseltamivir resistance among hospitalized adults, including its potential for nosocomial spread.
51. Weinstock DM, Zuccotti G: The evolution of influenza resistance and treatment. JAMA 301(10), 1066-1069 (2009).
52. Hayden FG: Antiviral resistance in influenza viruses--implications for management and pandemic response. N. Engl. J. Med. 354(8), 785-788 (2006).
53. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S: Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4(7), E1000103 (2008). ■■ A critical study that defined the molecular virology of oseltamivir resistance among circulating H1N1 viruses in Europe.
54. de Jong MD, Tran TT, Truong HK et al.: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005).
55. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178(5), 1257-1262 (1998).
56. Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348(9), 867-868 (2003).
57. Gubareva LV, Webster RG, Hayden FG: Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53(1), 47-61 (2002).
58. McKimm-Breschkin JL: Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir. Med. 4(2), 107-116 (2005).
59. Zambon M, Hayden FG: Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49(3), 147-156 (2001). (Pubitemid 32322468)
60. Hatakeyama S, Sakai-Tagawa Y, Kiso M et al.: Enhanced expression of an α2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43(8), 4139-4146 (2005). (Pubitemid 41129710)
61. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD: Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77(15), 8418-8425 (2003). ■ A study documenting the limitations associated with standard cell lines in detecting antiviral resistance emergence in influenza isolates. (Pubitemid 36871470)
62. Tisdale M: Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10(1), 45-55 (2000).
63. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB: Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D-N- acetylneuraminate) substrate. Anal. Biochem. 94(2), 287-296 (1979). (Pubitemid 9173017)
64. Lackenby A, Democratis J, Siqueira MM, Zambon MC: Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 13(6), 809-820 (2008).
65. Guo L, Garten RJ, Foust AS et al.: Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res. 82(1), 29-33 (2009).
66. Pabbaraju K, Tokaryk KL, Wong S, Fox JD: Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. J. Clin. Microbiol. 46(9), 3056-3062 (2008).
67. Merante F, Yaghoubian S, Janeczko R: Principles of the xTAG respiratory viral panel assay (RVP Assay). J. Clin. Virol. 40(Suppl. 1), S31-S35 (2007). (Pubitemid 350298971)
68. Centers for Disease Control and Prevention (CDC): Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly Rep. 58(32), 893-896 (2009).
69. Centers for Disease Control and Prevention (CDC): Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb. Mortal. Wkly Rep. 58(35), 969-972 (2009).
70. McCaw JM, Wood JG, McCaw CT, McVernon J: Impact of emerging antiviral drug resistance on influenza containment and spread: influenza of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 3, E2362 (2008).
71. Ison MG, Gnann JW Jr, Nagy-Agren S et al.: Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8(3), 183-190 (2003). ■ The only study of combination therapy for influenza in man that documented a reduced rate of resistance emergence with combination therapy. (Pubitemid 36960891)
72. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-2009 influenza season. CDC Health Advisory (2008) http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279
73. Main website for all seasonal influenza information from the CDC www.cdc.gov/flu
74. CDC website with antiviral recommendations with regard to the pandemic influenza A/H1N1 2009 www.cdc.gov/h1n1flu/recommendations.htm